title: Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.
abstract: Haploidentical transplantation can extend the opportunity for transplantation to almost all patients who lack an HLA-matched donor. Advances in the field of haploidentical transplantation have led to a marked decrease in treatment-related mortality, allowing investigators to focus on developing rationale pre- and peri-remission therapies aimed at preventing disease relapse after transplantation. Because of widespread availability, low treatment-related mortality, and cost, haploidentical donors may become the preferred "alternative" donors for allogeneic hematopoietic stem cell transplantation. One of the major advantages of using a related donor is the possibility of collecting or generating additional cellular products from the same immediately available donor, which will not be rejected. Infusion of these cells in the peri-transplantation period, derived from the same immune system, is opening the possibility of markedly enhancing the antitumor effects of the graft and hastening immunologic reconstitution after transplantation.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas; Division of Hematology, Department of Internal Medicine, Faculty of Medicine Thammasat University, Thailand.
authors.forename: Piyanuch
authors.initials: P
authors.lastname: Kongtim
authors.affiliation: Department of Pediatrics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Dean A
authors.initials: DA
authors.lastname: Lee
authors.affiliation: Department of Pediatrics, University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Laurence J N
authors.initials: LJ
authors.lastname: Cooper
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: sciurea@mdanderson.org.
authors.forename: Stefan O
authors.initials: SO
authors.lastname: Ciurea
mesh_terms: D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D041722:Genes, Transgenic, Suicide; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006648:Histocompatibility; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000637:transplantation; D019520:Living Donors / Q000600:supply & distribution; D008212:Lymphocyte Depletion / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000627:therapeutic use; D012235:Rhodamines / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000637:transplantation*; D014181:Transplantation Immunology
chemical_list: C000605956:CD19-specific chimeric antigen receptor; D006680:HLA Antigens; D017319:Photosensitizing Agents; D011948:Receptors, Antigen, T-Cell; D012235:Rhodamines; D003520:Cyclophosphamide; C121365:4,5-dibromorhodamine 123
keywords: Alpha-beta T cell depletion; Cellular therapy; Chimeric antigen receptor T cells; Donor lymphocyte infusion; Haploidentical transplantation; Natural killer cells; Post-transplantation cyclophosphamide